Last reviewed · How we verify
Oxervate
At a glance
| Generic name | Oxervate |
|---|---|
| Also known as | Cenegermin |
| Sponsor | Dompé Farmaceutici S.p.A |
| Target | High affinity nerve growth factor receptor, Tumor necrosis factor receptor superfamily member 16 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Approved indications
- Neurotrophic keratitis
Common side effects
- Eye pain
- Ocular hyperemia
- Eye inflammation
- Increased lacrimation
- Corneal deposits
- Foreign body sensation
- Ocular inflammation
- Tearing
Key clinical trials
- DEFENDO Long Term Follow-up Study in Stage 1 NK Patients
- Study to Evaluate Safety and Efficacy of Cenegermin (Oxervate®) vs Vehicle in Severe Sjogren's Dry Eye Disease (PHASE3)
- Study to Evaluate OXERVATE® in Patients With Stage 1 Neurotrophic Keratitis (PHASE4)
- Corneal Neurotization vs. Cenergermin for Neurotrophic Keratitis: A Pilot Study (NA)
- DOMPE -MT Neurotrophic Keratitis (PHASE4)
- Corneal Nerves After Treatment With Cenegermin
- Open-label Trial to Evaluate Efficacy and Safety of rhNGF on Corneal Thickness Via AS-OCT in Neurotrophic Keratitis (PHASE4)
- Safety and Efficacy Study on Cenegermin (Oxervate®) vs Vehicle in Severe Sjogren's Dry Eye Disease (PROTEGO-1 Study) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Oxervate CI brief — competitive landscape report
- Oxervate updates RSS · CI watch RSS
- Dompé Farmaceutici S.p.A portfolio CI